Sweigart v. Workers' Compensation Appeal Board

920 A.2d 962, 2007 Pa. Commw. LEXIS 136
Commonwealth Court of Pennsylvania·Decided April 4, 2007·Published·Cited by 9 cases

Opinion

OPINION BY

Judge FRIEDMAN.

Craig Sweigart (Claimant) petitions for review of the August 25, 2006, order of the Workers’ Compensation Appeal Board (WCAB) affirming the decision of a workers’ compensation judge (WCJ) to deny Claimant’s Petition for Review of Utilization Review Determination (UR Petition). We affirm in part and reverse in part.

On March 16,1989, Claimant sustained a low back injury during the course and scope of his employment with Burnham Corporation (Employer). On December 11, 2003, Employer filed a utilization review (UR) request, seeking review of the reasonableness and necessity of diagnostic testing, office visits, injections, medication and blood patches provided by R.S. Mathews, M.D., from November 6, 2003, and ongoing. Stanley Askin, M.D., who performed the UR, determined that the medical care was not reasonable or necessary. [964] Claimant filed the UR Petition, and hearings were held before the WCJ. (WCJ’s op. at 1.)

At the hearings, Employer presented Dr. Askin’s UR determination. Although the UR request sought review of diagnostic testing and injections, Dr. Askin indicated that no diagnostic testing or injections were documented during the time frame under review. There were only three office visits. With respect to office visits on November 6, 2003, and November 25, 2003, for the purpose of administering blood patches1 to manage a complication from an earlier injection, Dr. Askin stated that he found no justification in Dr. Mathews’ records for any intervention in Claimant’s nerve roots or epidural space.2 With respect to Claimant’s office visit on December 3, 2003, for the purpose of prescribing Maxidone for Claimant, Dr. Askin stated that the chronic prescription of opioid medications is no more effective in relieving low back pain than safer analgesics.3 Thus, Dr. Askin did not consider the office visits, medication and blood patches to be reasonable or necessary.

Claimant testified on his own behalf and introduced medical records from Dr. Mathews. In a procedure report dated November 6, 2003, Dr. Mathews stated that he performed a transforaminal epidural blood patch on that date because Claimant was experiencing a low pressure headache. In an office note dated November 25, 2003, Dr. Mathews stated that Claimant was experiencing repeated headaches following a transforaminal epidural lysis of adhesions. Dr. Mathews suspected that Claimant had a dural leak and, thus, administered another blood patch. In his reports dated November 12, 2004, and December 10, 2004, Dr. Mathews stated that he advised Claimant that further injections would not likely be prudent; instead of further injections, Dr. Mathews prescribed Maxidone, as needed.

After considering the evidence, the WCJ accepted Dr. Askin’s expert opinion that Dr. Mathews’ medical treatment was not reasonable or necessary because, unlike Dr. Mathews, Dr. Askin based his opinion on sources that he footnoted in his report. (WCJ’s Findings of Fact, No. 11.) Thus, on July 7, 2005, the WCJ denied and dismissed Claimant’s UR Petition. Claimant appealed to the WCAJ3, which affirmed. Claimant now petitions this court for review.4

[965] I.Collateral Estoppel

Claimant first argues that Employer is collaterally estopped from challenging Dr. Mathews’ care of Claimant because, in a decision dated May 23, 2001, another WCJ concluded that Dr. Mathews’ care of Claimant was reasonable and necessary. We disagree.

Collateral estoppel acts to foreclose litigation in a later action of issues of law or fact that were actually litigated and were necessary to a previous final judgment. Knouse v. Workers’ Compensation Appeal Board (G.O.D., Inc.), 886 A.2d 329 (Pa.Cmwlth.2005).

Here, with respect to Maxidone, Claimant testified that he did not take that medication before late 2003, (R.R. at 34a), and the 2001 decision does not even mention Maxidone, (see R.R. at 87a-96a). Thus, the 2001 decision could not have litigated the reasonableness and necessity of Maxidone. Similarly, with respect to the blood patches, the 2001 decision does not mention blood patches. Thus, the earlier decision could not have litigated the reasonableness and necessity of the blood patches. Therefore, we reject Claimant’s collateral estoppel argument.

II.34 Pa.Code § 127.471(a)

Claimant next argues that Dr. Asian’s report fails to comply with 34 Pa.Code § 127.471(a), which states that reviewers may consider whether other courses of treatment exist, but reviewers may not determine that the treatment under review is unreasonable or unnecessary solely on the basis that other courses of treatment exist. Claimant asserts that Dr. Askin found Maxidone unreasonable and unnecessary solely because alternative pain medications exist. We disagree.

Dr. Askin found Maxidone unreasonable and unnecessary because it was an opioid and because other medications were safer. In other words, in addition to the fact that other equally effective medications existed, Dr. Askin was concerned about the risk to the patient. Thus, Dr. Askin did not find Maxidone unreasonable and unnecessary solely because other equally effective medications existed.

III.34 Pa.Code § 127.470(b)

Claimant argues that Dr. Askin’s report fails to comply with 34 Pa.Code § 127.470(b), which states that reviewers may not consider or decide “quality of care” issues. Claimant asserts that Dr. Askin’s preference for safer medications than Maxidone is a “quality of care” issue. We disagree.

We interpret “quality of care” in 34 Pa. Code § 127.470(b) as separate and distinct from the reasonableness and necessity of treatment. Otherwise, the regulation would preclude review of specific treatment for reasonableness and necessity because such review would involve “quality of care” considerations. It is entirely appropriate for a reviewer, in determining the reasonableness and necessity of a prescribed medication, to consider the risk to the patient, i.e., whether it was reasonable and necessary for the provider to expose the patient to the level of risk presented by the medication.

IV.34 Pa.Code § 127.472

Claimant next argues that Dr. Asian’s report fails to comply with 34 Pa. Code § 127.472, which states that reports shall contain a detailed explanation of the reasons for the conclusions reached by the reviewer. Claimant asserts that Dr. As-kin’s report does not contain a detailed explanation for his conclusion that the [966] blood patches were not reasonable or necessary to treat headaches that resulted from an injection and a spinal fluid leak. We agree.

Free access — add to your briefcase to read the full text and ask questions with AI

Sweigart v. Workers' Compensation Appeal Board, 920 A.2d 962, 2007 Pa. Commw. LEXIS 136 (Pa. Ct. App. 2007).

920 A.2d 962 (Sweigart v. Workers' Compensation Appeal Board) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

J.M. Rotegliano v. Clinton Hospital Corp. (WCAB)
Commonwealth Court of Pennsylvania, 2022
M.A. Mushow v. Doyle & Roth Mfg. (WCAB)
Commonwealth Court of Pennsylvania, 2022
F. Hughes v. Wawa, Inc. (WCAB)
Commonwealth Court of Pennsylvania, 2021
J. Golembesky v. WCAB (Worth & Company, Inc.)
Commonwealth Court of Pennsylvania, 2019
A. Stamis v. WCAB (Delaware County IU)
Commonwealth Court of Pennsylvania, 2016
Bedford Somerset MHMR v. Workers' Compensation Appeal Board (Turner)
51 A.3d 267 (Commonwealth Court of Pennsylvania, 2012)
City of Philadelphia v. Workers' Compensation Appeal Board
34 A.3d 871 (Commonwealth Court of Pennsylvania, 2011)
Gary v. Workers' Compensation Appeal Board
18 A.3d 1282 (Commonwealth Court of Pennsylvania, 2011)